Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tryptophan Clear all
Active, not recruiting Phase 2 Interventional

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

NCT03935685
View directory record Official record
Conditions
Glioma of Brain
Interventions
Mirtazapine (Remeron)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 18, 2026, 6:19 AM EDT
Completed No phase listed Observational

Tryptophan Metabolism in Human Brain Tumors

NCT02367469
View directory record Official record
Conditions
Brain Tumors
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
13 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 18, 2026, 6:19 AM EDT
Recruiting Phase 3 Interventional

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

NCT04423211
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
Radiation · Drug · Procedure + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
341
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

NCT01681095
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Valvular Heart Disease
Interventions
Custodiol HTK, Cold Blood Cardioplegia
Drug
Lead sponsor
Marc Sakwa, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 18, 2026, 6:19 AM EDT
Terminated Phase 2 Interventional

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

NCT03924154
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
RVT-1201, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 18, 2026, 6:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders

NCT00097175
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 18, 2026, 6:19 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of Exercise and 5-HTP on Cortisol Levels

NCT02187341
View directory record Official record
Conditions
Plasma Cortisol
Interventions
5-HTP, Placebo
Dietary Supplement
Lead sponsor
Benedictine University
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lisle, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

NCT02073123
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
Indoximod, Ipilimumab, Nivolumab, Pembrolizumab
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 18, 2026, 6:19 AM EDT
Recruiting No phase listed Observational

Optima Coil Performance in The Interventional Management of Intracranial Aneurysms Registry

NCT06282939
View directory record Official record
Conditions
Intracranial Aneurysm
Interventions
OPTIMA and OPTIMAX Coils manufactured by Balt USA
Device
Lead sponsor
HCA Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium

NCT00865202
View directory record Official record
Conditions
Post-operative Delirium
Interventions
L-tryptophan supplementation, placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

NCT01560923
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Indoximod, Sipuleucel-T, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 4 Interventional

Treatment of Obsessive-Compulsive Disorder

NCT00000373
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
olanzapine + fluoxetine, placebo + fluoxetine
Drug
Lead sponsor
University of Florida
Other
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2003
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

NCT03453489
View directory record Official record
Conditions
Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
Interventions
Carbon C 11 Alpha-methyltryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography, Telotristat Etiprate
Other · Procedure · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 18, 2026, 6:19 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

NCT04484818
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Darolutamide, Goserelin Acetate, Leuprolide Acetate, Placebo Administration, Quality-of-Life Assessment, Triptorelin
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
115
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 88 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

NCT02077881
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Interventions
Nab-Paclitaxel, Gemcitabine, Indoximod
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
11
States / cities
Palo Alto, California • Augusta, Georgia • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Daily Supplementation of 5-HTP on Body Composition

NCT05216406
View directory record Official record
Conditions
Body Composition
Interventions
5-HTP, Placebo
Dietary Supplement · Other
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 2 Interventional

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

NCT01792050
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Docetaxel, Placebo, Indoximod, Paclitaxel
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Gainesville, Florida • Tampa, Florida • Titusville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 1 Interventional

F-Tryptophan PET/CT in Human Cancers

NCT05556473
View directory record Official record
Conditions
Intracranial Glioma, Metastatic Brain Tumor, Breast Cancer, Neuroendocrine Tumors, Rectal Cancer
Interventions
1-(2-[18F]FLUOROETHYL)-L-Tryptophan
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

NCT03089606
View directory record Official record
Conditions
Melanoma
Interventions
FDG PET/CT scan, C11-AMT PET scan, Pembrolizumab, CT scan
Diagnostic Test · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dietary Intake of Tryptophan and Metformin Response

NCT02184832
View directory record Official record
Conditions
Metformin Response, Fasting Glucose, Tryptophan Concentration, Metformin Concentration, Diet Tolerability
Interventions
Metformin, Low tryptophan diet, High tryptophan diet
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 18, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 18, 2026, 6:19 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

NCT05834296
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo
Biological · Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 6:19 AM EDT
Terminated Phase 1 Interventional

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

NCT00739609
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Solid Tumors
Interventions
1-methyl-D-tryptophan
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 18, 2026, 6:19 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females

NCT02922725
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-hydroxytryptophan and Creatine, Placebo control
Drug · Other
Lead sponsor
Brent Michael Kious, MD, PhD
Other
Eligibility
25 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 18, 2026, 6:19 AM EDT